Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes

Inclusion Criteria: * HEALTHY VOLUNTEERS * Healthy subjects aged 18-45 years inclusive * Healthy subjects are defined as individuals free from significant cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, neurological and psychiatric disease as determined by history, physical examination and clinical laboratory test results * Women who are not of childbearing potential * Signed and dated written informed consent obtained * Body mass index (BMI) within the range 19-30 kg/m\^2, inclusive * SUBJECTS WITH DIABETES * Subjects aged 40-70 years inclusive * Subjects diagnosed with type-2 diabetes and a duration of diabetes of more than 12 months * Women who are not of childbearing potential * Signed and dated written informed consent obtained * Fasting C-peptide at least 0.3 nmol/l and blood glucose at least 7 mmol/l * Subjects currently on diet and/or OHA (oral hypoglycemic agents) for at least six months * Body mass index (BMI) below 35 kg/m\^2 * HbA1c (glycosylated haemoglobin) below 11% * Stable on current medication for at least 3 weeks prior to dosing in this study Exclusion Criteria: * HEALTHY VOLUNTEERS * Clinically relevant abnormal history or physical findings (e.g. cancer) at the screening assessment, which could interfere with the objectives of the study or the safety of the subject's participation * Clinically relevant abnormalities of laboratory values or ECG at the screening evaluation * Presence of acute or chronic illness sufficient to invalidate the subject's participation in the study or to make it unnecessarily hazardous * Blood pressure and heart rate in seated position at the screening examination outside the ranges 90-150 mmHg systolic, 40-90 mmHg diastolic: heart rate 40-100 beats/min * History of drug or alcohol abuse (alcohol abuse is defined as intake of more than 28 units weekly in men and more than 21 units weekly in women) * Alcohol intake within 48 hours prior to visit * Evidence of drug abuse on urine testing at study entry * The subject smokes 10 cigarettes or more, or the equivalent, per day and is unable to refrain from smoking during 3 days prior to the first dosing day and during the confinement period * Hepatitis B surface antigen (HBsAg), Hepatitis C antibodies or HIV (human immunodeficiency virus) antibodies * History of significant drug allergy or drug hypersensitivity * SUBJECTS WITH DIABETES * Use of any drug (except for oral hypoglycaemic agents (OHAs)) which in the Investigator's opinion could interfere with the blood glucose level (e.g. insulin, systemic corticosteroids, thiazides) * Recurrent severe hypoglycaemia as judged by the Investigator * Clinically relevant abnormal history or physical findings (e.g. cancer) at the screening assessment, which could interfere with the objectives of the study or the safety of the subject's participation * Clinically relevant abnormalities of laboratory values or ECG at the screening evaluation * Presence of acute or chronic illness sufficient to invalidate the subject's participation in the study or to make it unnecessarily hazardous * Blood pressure and heart rate in seated position at the screening examination outside the ranges 110-160 mmHg systolic, 60-90 mmHg diastolic: heart rate 40-100 beats/min * History of drug or alcohol abuse (alcohol abuse is defined as intake of more than 28 units weekly in men and more than 21 units weekly in women) * Alcohol intake within 48 hours of visit * Evidence of drug abuse on urine testing at study entry * The subject smokes 10 cigarettes or more, or the equivalent, per day and is unable to refrain from smoking during 3 days prior to the first dosing day and during the confinement period * Hepatitis B surface antigen (HBsAg), Hepatitis C antibodies * History of significant drug allergy or drug hypersensitivity